News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Exercise Is an Important Ingredient in Ameliorating Anemia-Related Fatigue

May 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

LITTLE ROCK-For patients with cancer-related fatigue, "the first line of treatment, in my opinion, is to increase their hemoglobin levels so that they can begin an exercise program," noted William Evans, PhD. "Cancer patients suffering from primary fatigue should not be advised to increase the amount of daily rest. Rather, they should be counseled to carry out aerobic exercise," he explained. Dr. Evans serves as director, nutrition, metabolism, and exercise, and professor of geriatrics, physiology, and nutrition at the University of Arkansas for Medical Sciences in Little Rock.

LITTLE ROCK—For patients with cancer-related fatigue, "the first line of treatment, in my opinion, is to increase their hemoglobin levels so that they can begin an exercise program," noted William Evans, PhD. "Cancer patients suffering from primary fatigue should not be advised to increase the amount of daily rest. Rather, they should be counseled to carry out aerobic exercise," he explained. Dr. Evans serves as director, nutrition, metabolism, and exercise, and professor of geriatrics, physiology, and nutrition at the University of Arkansas for Medical Sciences in Little Rock.

An exercise physiologist by training, Dr. Evans noted that fatigue is related to reduced aerobic capacity, which can be measured by VO2max (cardiac output times the arterial/venous oxygen difference). VO2max varies enormously, with values ranging from 60 mL/kg/min. and up for professional athletes, to 50 and below for sedentary individuals. In cancer patients, VO2max levels have been measured below 20 mL/kg/min.

Benefits of rHuEPO

Dr. Evans reviewed one randomized prospective study examining the protective effects of recombinant erythropoietin (rHuEPO) on metabolic and exercise capacity in cancer patients losing weight. The study involved 108 cancer patients, most with gastrointestinal cancers, randomized to oral indomethacin alone or with rHuEPO.

Despite being "somewhat complicated by a huge drop-out rate," the results clearly showed that hemoglobin levels and exercise capacity continued to drop in patients who did not receive rHuEPO, while patients who received it maintained relatively high hemoglobin levels of about 13 g/dL and increased their exercise capacity (see Figure 1). "The conclusion was that anemia is effectively overcome by rHuEPO in unselected cancer patients. Treatment of anemia preserved physical function, defined as exercise power and whole body metabolic efficiency," Dr. Evans said. "There is a remarkably strong relationship between change in VO

2

max and change in hemoglobin," he continued, "and at submaximal exercise capacities, restoring hemoglobin levels results in increased cardiac output and a change in heart rate and lactate."

Cancer fatigue is probably due not only to anemia, but also to loss of muscle mass resulting from cachexia, and severe deconditioning, Dr. Evans said. "Many cancer patients who become anemic and lose muscle mass are likely to be very inactive. Increasing their hematocrit may allow cancer patients to participate in a regular conditioning program to resolve this issue of severe deconditioning."

Reviewing the somewhat sparse literature on the subject, Dr. Evans found that cancer patients losing weight or suffering from severe fatigue had greatly reduced VO2max, equivalent only to the oxygen cost of simply walking at a normal pace of about 2½ miles per hour. "Most of the activities of daily living are well above the so-called anaerobic threshold of most cancer patients," Dr. Evans said. "That tells us two things: that their fatigue is related to their anemia and low VO2max, but also their severe deconditioning." The anaerobic threshold is the point when muscles begin producing more lactic acid than they consume and spill lactic acid into the blood, increasing respiration rate. Above the threshold it is extremely difficult to work without becoming fatigued.

Effects of Conditioning

One of the few studies looking at physical training for cancer patients, involved five cancer patients with chemotherapy-related fatigue. Rather than receiving rHuEPO, the patients were simply trained on a treadmill at a speed corresponding to their anaerobic threshold. As the patients’ lactate levels and heart rates decreased, the treadmill speed and duration of exercise increased to about 35 minutes 5 days per week.

The researchers concluded that "the loss of energy originated in extreme muscular deconditioning related to illness and treatment and the recommendations for rest had worked paradoxically. That is, most of these patients had been told by their oncologist that if they were tired they should go home and take a nap," Dr. Evans said. "In fact, that’s probably the worst recommendation that they could be given because inactivity induces muscle catabolism and prolonged rest can cause a further loss of performance."

Exercise training in cancer patients "can cause an almost immediate plasma volume expansion and increase in cardiac output, improve anaerobic threshold, and increase the VO2max," he explained. "This will improve activities of daily living and cause a significant increase in skeletal muscle metabolism with increases in capillary density."

Strength Training Possible

A small study published in the Journal of the American Medical Association 10 years ago showed the benefits of intensive weight training among 10 very old and frail nursing home patients. "We were able to triple muscle strength after 8 weeks of training and we caused a 10% increase in their muscle mass," Dr. Evans reported.

A follow-up study in the same nursing home tested the effects of exercise and nutritional supplements among 100 frail and elderly patients. The supplements were not successful in getting elderly persons to increase their food intake. "The only group, in fact, that increased their food intake was the group that exercised," Dr. Evans reported. Total food intake was strongly related to increase in muscle size. "Importantly, the subjects who exercised had decreased depressive symptoms so that it really had a quite remarkable effect," he added.

"Oncologists and physicians resist the concept that exercise may be appropriate for their patients, either because they’re too frail or they’re not going to like it, or they’re not going to be able to do it, and I can tell you if these people [frail elderly patients] can do it, virtually anybody can do it."

Articles in this issue

Prognosis Good for Local Recurrence After Lumpectomy
Long-Term Use of Actiq Safe and Effective for Breakthrough Pain
Youth Exposed to Tobacco Promotions
Green Tea May Help Prevent Certain Gastrointestinal Cancers
EGFR Inhibitor Effective as Salvage Therapy for NSCLC
Targeted Filgrastim Support Allows Planned Chemotherapy Doses
Low Risk of CHF With Paclitaxel/Trastuzumab Adjuvant Rx
Anxiety, Depression in Women at High Risk for Breast Cancer
NCCN Updates its Treatment Guidelines for Breast Cancer
Danny Glover ‘Acting’ as Spokesman for Anemia LifeLine
Health Care Spending Expected to Soar
Cancer Center Unit Redesigned to Create Healing Environment
Current Treatment Options for Aplastic Anemia and Myelodysplastic Syndrome
Study Shows That New State Regulations Encourage Appropriate Pain Management
Rituximab Combo Is Effective for Relapsed CLL-Associated Autoimmune Hemolytic Anemia
Related Videos
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on CML
Experts on MM
Experts on CML
Experts on MM
KOLs smiling at camera.
KOLs smiling at camera.
Related Content

Amivantamab Significantly Improves PFS Vs Chemotherapy in EGFR+ NSCLC

October 4th 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

BDC-1001 Receives FDA Orphan Drug Designation in Gastric Cancers

October 4th 2023

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023

BI 764532 Earns FDA FTD in SCLC and Extrapulmonary Neuroendocrine Carcinoma

October 3rd 2023

FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria

October 3rd 2023

Amivantamab Significantly Improves PFS Vs Chemotherapy in EGFR+ NSCLC

October 4th 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

BDC-1001 Receives FDA Orphan Drug Designation in Gastric Cancers

October 4th 2023

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023

BI 764532 Earns FDA FTD in SCLC and Extrapulmonary Neuroendocrine Carcinoma

October 3rd 2023

FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria

October 3rd 2023

Amivantamab Significantly Improves PFS Vs Chemotherapy in EGFR+ NSCLC

October 4th 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

BDC-1001 Receives FDA Orphan Drug Designation in Gastric Cancers

October 4th 2023

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023

BI 764532 Earns FDA FTD in SCLC and Extrapulmonary Neuroendocrine Carcinoma

October 3rd 2023

FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria

October 3rd 2023
Related Content
Advertisement

Investigators will present overall survival and objective response data from the phase 3 MARIPOSA trial assessing amivantamab in EGFR exon 19 deletion–positive non–small cell lung cancer at a future scientific meeting.

Amivantamab Significantly Improves PFS Vs Chemotherapy in EGFR+ NSCLC

October 4th 2023
Article

Investigators will present overall survival and objective response data from the phase 3 MARIPOSA trial assessing amivantamab in EGFR exon 19 deletion–positive non–small cell lung cancer at a future scientific meeting.


Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023
Podcast

Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.


Two phase 2 studies are assessing the efficacy of BDC-1001 in several disease states, including colorectal, gastroesophageal, endometrial, and breast cancer.

BDC-1001 Receives FDA Orphan Drug Designation in Gastric Cancers

October 4th 2023
Article

Two phase 2 studies are assessing the efficacy of BDC-1001 in several disease states, including colorectal, gastroesophageal, endometrial, and breast cancer.


Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.


Data from a phase 1 trial highlight a clinically acceptable safety profile for BI 764532 in patients with extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinomas.

BI 764532 Earns FDA FTD in SCLC and Extrapulmonary Neuroendocrine Carcinoma

October 3rd 2023
Article

Data from a phase 1 trial highlight a clinically acceptable safety profile for BI 764532 in patients with extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinomas.


Patients with paroxysmal nocturnal hemoglobinuria can now self-administer pegcetacoplan subcutaneously following the FDA’s approval of an injector.

FDA Approves Pegcetacoplan Injector for Paroxysmal Nocturnal Hemoglobinuria

October 3rd 2023
Article

Patients with paroxysmal nocturnal hemoglobinuria can now self-administer pegcetacoplan subcutaneously following the FDA’s approval of an injector.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.